Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LNCR3
MCID: LNG064
MIFTS: 80

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Cancer Susceptibility 3

About this section

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 58 13 74
Lung Adenocarcinoma 39 12 54 30 6 15 17
Adenocarcinoma of Lung 58 12 77 74
Adenocarcinoma of Lung, Susceptibility to 58
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 74
Nonsmall Cell Adenocarcinoma 12
Adenocarcinoma Lung 56
Lncr3 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3910
OMIM 58 612571
MeSH 45 C538231
NCIt 51 C27745 C3512
Sources

Summaries for Lung Cancer Susceptibility 3

About this section
NIH Rare Diseases : 54 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting.

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to mucinous lung adenocarcinoma and lung cancer. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Pemetrexed and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A lung cancer that derives from epithelial cells of glandular origin.

Wikipedia : 77 Adenocarcinoma of the lung (also known as pulmonary adenocarcinoma) is the most common type of lung... more...

Description from OMIM: 612571
Sources

Related Diseases for Lung Cancer Susceptibility 3

About this section

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 455)
# Related Disease Score Top Affiliating Genes
1 mucinous lung adenocarcinoma 35.1 ALK EGFR ERBB2 HRAS KRAS ROS1
2 lung cancer 34.4 AKT1 ALK BRAF CDK4 EGFR ERBB2
3 lung squamous cell carcinoma 33.6 AKT1 ALK BRAF EGFR FGFR3 HRAS
4 lung papillary adenocarcinoma 33.5 ALK NFE2L2 TP53
5 adenocarcinoma 32.5 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
6 breast cancer 31.8 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
7 thyroid cancer 31.7 AKT1 BRAF CTNNB1 EGFR HRAS KRAS
8 small cell cancer of the lung 31.6 AKT1 EGFR PIK3CA TP53
9 colorectal cancer 31.6 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
10 sarcoma 31.6 BRAF CDK4 CTNNB1 HRAS KRAS PIK3CA
11 hepatocellular carcinoma 31.5 AKT1 CDK4 CTNNB1 EGFR HRAS KRAS
12 ovarian cancer 31.4 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
13 prostate cancer 31.3 AKT1 CDK4 CTNNB1 EGFR ERBB2 HRAS
14 melanoma 31.3 BRAF CDK4 MAP2K1 NRAS TP53
15 cervical cancer 31.2 AKT1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
16 gastric cancer 31.2 AKT1 CTNNB1 EGFR ERBB2 KRAS PIK3CA
17 pancreatic cancer 31.1 AKT1 CDK4 CTNNB1 EGFR ERBB2 HRAS
18 gastric adenocarcinoma 31.1 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
19 adenoid cystic carcinoma 31.1 AKT1 CTNNB1 ERBB2 HRAS KRAS PIK3CA
20 squamous cell carcinoma 31.1 AKT1 BRAF CTNNB1 EGFR ERBB2 FGFR3
21 cholangiocarcinoma 31.1 AKT1 BRAF CTNNB1 EGFR ERBB2 KRAS
22 glioblastoma 31.1 AKT1 ALK BRAF CDK4 EGFR ERBB2
23 glioma 31.1 BRAF CDK4 EGFR ERBB2 PIK3CA TP53
24 pancreas adenocarcinoma 31.0 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
25 differentiated thyroid carcinoma 30.9 ALK BRAF EGFR HRAS KRAS NRAS
26 suppression of tumorigenicity 12 30.9 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
27 ovarian serous cystadenocarcinoma 30.9 AKT1 BRAF ERBB2 HRAS NRAS PIK3CA
28 breast adenocarcinoma 30.9 AKT1 EGFR ERBB2 KRAS PIK3CA SMAD4
29 bladder cancer 30.9 CDK4 EGFR ERBB2 FGFR3 HRAS KRAS
30 colorectal adenocarcinoma 30.9 BRAF CTNNB1 EGFR HRAS KRAS TP53
31 endometrial adenocarcinoma 30.9 AKT1 CTNNB1 EGFR ERBB2 KRAS TP53
32 gastrointestinal stromal tumor 30.8 AKT1 BRAF EGFR KRAS TP53
33 ovarian cancer 1 30.8 AKT1 ERBB2 KRAS PIK3CA TP53
34 adrenocortical carcinoma, hereditary 30.8 BRAF CTNNB1 NRAS PIK3CA TP53
35 melanoma, uveal 30.8 BRAF CDK4 NRAS
36 large cell carcinoma 30.8 EGFR ROS1 STK11
37 adenoma 30.8 BRAF CTNNB1 KRAS SMAD4 TP53
38 bile duct adenocarcinoma 30.8 AKT1 HRAS KRAS TP53
39 intrahepatic cholangiocarcinoma 30.7 CTNNB1 EGFR KRAS TP53
40 lymphoma, non-hodgkin, familial 30.7 ALK BRAF NRAS PIK3CA TP53
41 familial adenomatous polyposis 30.6 CTNNB1 KRAS SMAD4 TP53
42 thymoma 30.6 AKT1 EGFR HRAS TP53
43 mucinous adenocarcinoma 30.5 ALK EGFR KRAS
44 signet ring lung adenocarcinoma 12.3
45 bronchiolo-alveolar adenocarcinoma 11.9
46 tumor predisposition syndrome 11.2
47 large intestine cancer 11.1 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
48 lung occult adenocarcinoma 11.1
49 lung cancer susceptibility 1 11.1
50 lung acinar adenocarcinoma 11.1

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3
Sources

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

About this section

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

27 (show top 50) (show all 82)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.33 BRAF EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00106-A-0 11.33 KRAS
3 Decreased viability GR00107-A-1 11.33 MAP2K1
4 Decreased viability GR00221-A-1 11.33 AKT1 ALK EGFR PIK3CA FGFR3 HRAS
5 Decreased viability GR00221-A-2 11.33 AKT1 PIK3CA FGFR3 HRAS KRAS RAF1
6 Decreased viability GR00221-A-3 11.33 AKT1 ERBB2 FGFR3 HRAS MAP2K1 NRAS
7 Decreased viability GR00221-A-4 11.33 AKT1 ALK BRAF EGFR ERBB2 PIK3CA
8 Decreased viability GR00231-A 11.33 RAF1
9 Decreased viability GR00301-A 11.33 BRAF KRAS RAF1
10 Decreased viability GR00342-S-1 11.33 MAP2K1 ROS1
11 Decreased viability GR00342-S-2 11.33 MAP2K1
12 Decreased viability GR00342-S-3 11.33 MAP2K1
13 Decreased viability GR00381-A-1 11.33 BRAF KRAS
14 Decreased viability GR00402-S-2 11.33 AKT1 ALK BRAF EGFR ERBB2 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.96 PRKN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.96 CTNNB1 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.96 BRAF
18 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.96 CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.96 FGFR3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.96 CDK4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.96 PIK3CA CDK4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.96 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.96 KRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.96 EGFR FGFR3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.96 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.96 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.96 AKT1 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.96 ERBB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.96 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.96 BRAF PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.96 KRAS ERBB2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.96 PRKN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.96 AKT1 BRAF CTNNB1 KRAS PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.96 PIK3CA EGFR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.96 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.96 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.96 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.96 PRKN
39 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.96 PRKN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.96 ERBB2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.96 CDK4 EGFR
42 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.96 EGFR
43 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.96 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.96 KRAS
45 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.96 BRAF
46 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.96 BRAF
47 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.96 BRAF ERBB2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.96 PRKN
49 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.96 AKT1 PIK3CA CDK4
50 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.96 EGFR

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.57 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
3 behavior/neurological MP:0005386 10.56 AKT1 ALK BRAF CDK4 CTNNB1 ERBB2
4 cardiovascular system MP:0005385 10.56 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.54 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
6 integument MP:0010771 10.53 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
7 endocrine/exocrine gland MP:0005379 10.5 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
8 mortality/aging MP:0010768 10.49 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
9 embryo MP:0005380 10.48 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
10 craniofacial MP:0005382 10.46 BRAF CTNNB1 EGFR ERBB2 FGFR3 HRAS
11 digestive/alimentary MP:0005381 10.46 BRAF CDK4 CTNNB1 EGFR ERBB2 FGFR3
12 neoplasm MP:0002006 10.43 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
13 nervous system MP:0003631 10.41 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
14 immune system MP:0005387 10.4 AKT1 BRAF CDK4 CTNNB1 EGFR FGFR3
15 hematopoietic system MP:0005397 10.39 AKT1 BRAF CDK4 CTNNB1 EGFR FGFR3
16 normal MP:0002873 10.33 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
17 muscle MP:0005369 10.31 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
18 liver/biliary system MP:0005370 10.3 AKT1 BRAF CDK4 CTNNB1 EGFR KRAS
19 no phenotypic analysis MP:0003012 10.21 CTNNB1 EGFR FGFR3 HRAS KRAS NRAS
20 hearing/vestibular/ear MP:0005377 10.19 BRAF CTNNB1 EGFR FGFR3 KRAS MAP2K1
21 limbs/digits/tail MP:0005371 10.19 BRAF CTNNB1 EGFR ERBB2 FGFR3 KRAS
22 reproductive system MP:0005389 10.13 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
23 renal/urinary system MP:0005367 10.06 BRAF CDK4 CTNNB1 EGFR FGFR3 HRAS
24 respiratory system MP:0005388 10 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
25 pigmentation MP:0001186 9.97 ALK BRAF CDK4 CTNNB1 EGFR KRAS
26 skeleton MP:0005390 9.89 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
27 vision/eye MP:0005391 9.44 ALK BRAF CDK4 CTNNB1 EGFR FGFR3
Sources

Drugs & Therapeutics for Lung Cancer Susceptibility 3

About this section

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
5
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
6
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
8 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 183319-69-9 176871
10 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Endostatins Phase 4 71581480
16 Endostar protein Phase 4,Phase 2
17 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
18 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 tyrosine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
23
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
24
afatinib Approved Phase 3,Phase 2 850140-72-6, 439081-18-2 10184653
25
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
26
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
27
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
28
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
29
Loperamide Approved Phase 3 53179-11-6 3955
30
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
31
Vinblastine Approved Phase 3 865-21-4 13342 241903
32
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
33
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
34
Ceritinib Approved Phase 3,Phase 2 1032900-25-6
35
Hydroxocobalamin Approved Phase 3,Not Applicable 13422-51-0 11953898 15589840
36
Methylcobalamin Approved, Experimental, Investigational Phase 3,Not Applicable 13422-55-4
37
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
38
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
39
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
40
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
41
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
42
Cyanocobalamin Approved, Nutraceutical Phase 3,Not Applicable 68-19-9 44176380
43
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
44
Cobalamin Experimental Phase 3,Not Applicable 13408-78-1 6857388
45 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
50 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 389)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
2 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
8 Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients Unknown status NCT01719536 Phase 3 Icotinib;Chemotherapy
9 Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma Unknown status NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
10 HS-PCI in Locally Advanced Adenocarcinoma of the Lung Unknown status NCT02341170 Phase 3
11 Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
12 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
13 First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker Completed NCT00455936 Phase 3 Gefitinib
14 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
15 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) Completed NCT01121393 Phase 3 Gemcitabine+Cisplatin;BIBW 2992
16 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation Completed NCT00949650 Phase 3 Pemetrexed;BIBW 2992;Cisplatin
17 ADAM-Afatinib Diarrhea Assessment and Management Completed NCT01814553 Phase 3 afatinib;loperamide
18 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
19 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
20 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
21 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
22 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
23 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
24 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
25 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
26 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
27 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
28 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
29 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
30 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
31 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
32 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
33 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
34 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
35 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
36 Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
37 Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma Recruiting NCT02518802 Phase 3 Gefitinib;Pemetrexed
38 Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
39 Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
40 Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Recruiting NCT02125240 Phase 3 Icotinib;Placebo
41 To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma Recruiting NCT03656393 Phase 3 Gefitinib;Vinorelbine;Carboplatin
42 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
43 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
44 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
45 Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer Active, not recruiting NCT01407822 Phase 2, Phase 3 Erlotinib;Gemcitabine/cisplatin
46 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
47 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
48 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
49 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
50 Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Sources

Genetic Tests for Lung Cancer Susceptibility 3

About this section

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 30
Sources

Anatomical Context for Lung Cancer Susceptibility 3

About this section

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

42
Lung, Brain, Lymph Node, Breast, Testes, Thyroid, Bone
Sources

Publications for Lung Cancer Susceptibility 3

About this section

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 4476)
# Title Authors Year
1
TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells. ( 30902544 )
2019
2
Morphological classification of pre-invasive lesions and early-stage lung adenocarcinoma based on CT images. ( 30903336 )
2019
3
Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection. ( 30906746 )
2019
4
High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma. ( 30907518 )
2019
5
The subpopulation of CD44-positive cells promoted tumorigenicity and metastatic ability in lung adenocarcinoma. ( 30908413 )
2019
6
Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. ( 30909965 )
2019
7
UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells. ( 30911937 )
2019
8
Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients ( 30912007 )
2019
9
Identification of tumor suppressor microRNAs by integrative microRNA and mRNA sequencing of matched tumor-normal pairs in lung adenocarcinoma. ( 30913346 )
2019
10
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. ( 30914311 )
2019
11
Risk of lung adenocarcinoma from smoking and radiation arises in distinct molecular pathways. ( 30915466 )
2019
12
Up-regulation of CKAP2L expression promotes lung adenocarcinoma invasion and is associated with poor prognosis. ( 30863084 )
2019
13
The prognostic value of Tiam1 correlates with its roles in epithelial-mesenchymal transition progression and angiogenesis in lung adenocarcinoma. ( 30863182 )
2019
14
The difference and relationship of CD4+ and CD8+ tumour infiltrating lymphocytes in lung adenocarcinoma. ( 30863488 )
2019
15
Treatment of stage IIIA-N2 EGFR-mutant non-small cell lung adenocarcinoma. ( 30863601 )
2019
16
Extracellular vesicle‑delivered miR‑505‑5p, as a diagnostic biomarker of early lung adenocarcinoma, inhibits cell apoptosis by targeting TP53AIP1. ( 30864684 )
2019
17
Downregulation of estrogen receptor β inhibits lung adenocarcinoma cell growth. ( 30864727 )
2019
18
Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells. ( 30867372 )
2019
19
Overexpression of LncRNA-UCA1 Correlates with Lung Adenocarcinoma Progression and Poor Prognosis. ( 30868851 )
2019
20
Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma. ( 30868896 )
2019
21
Diagnostic Value of MiR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma Lung Adenocarcinoma. ( 30868951 )
2019
22
Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk. ( 30870271 )
2019
23
Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing. ( 30872465 )
2019
24
PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma. ( 30872582 )
2019
25
Ground-glass opacity is a strong prognosticator for pathologic stage IA lung adenocarcinoma. ( 30876742 )
2019
26
Murrayanine Induces Cell Cycle Arrest, Oxidative Stress, and Inhibition of Phosphorylated p38 Expression in A549 Lung Adenocarcinoma Cells. ( 30879017 )
2019
27
Individual and combined toxicity of carboxylic acid functionalized multi-walled carbon nanotubes and benzo a pyrene in lung adenocarcinoma cells. ( 30879234 )
2019
28
TCTP promotes epithelial-mesenchymal transition in lung adenocarcinoma. ( 30881019 )
2019
29
miR-944 inhibits lung adenocarcinoma tumorigenesis by targeting STAT1 interaction. ( 30881499 )
2019
30
MiR-1-3p Inhibits Lung Adenocarcinoma Cell Tumorigenesis via Targeting Protein Regulator of Cytokinesis 1. ( 30881920 )
2019
31
ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report. ( 30882666 )
2019
32
Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma. ( 30883337 )
2019
33
Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy. ( 30885350 )
2019
34
MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma. ( 30885356 )
2019
35
PAMAM/polyhedral nanogold-modified probes with DNAase catalysis for the amperometric electrochemical detection of metastasis-associated lung adenocarcinoma transcript 1. ( 30886644 )
2019
36
Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT? ( 30887209 )
2019
37
Prognostic Impact of Tumor Spread Through Air Spaces in Sublobar Resection for 1A Lung Adenocarcinoma Patients. ( 30887374 )
2019
38
Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma. ( 30889488 )
2019
39
Gene expression classification of lung adenocarcinoma into molecular subtypes. ( 30892233 )
2019
40
Selective Detection of Human Lung Adenocarcinoma Cells Based on the Aptamer-Conjugated Self-Assembled Monolayer of Gold Nanoparticles. ( 30893795 )
2019
41
ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma. ( 30894682 )
2019
42
Aberrant Expression of Pseudogene-Derived lncRNAs as an Alternative Mechanism of Cancer Gene Regulation in Lung Adenocarcinoma. ( 30894871 )
2019
43
Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report. ( 30896626 )
2019
44
Screening of important lncRNAs associated with the prognosis of lung adenocarcinoma, based on integrated bioinformatics analysis. ( 30896819 )
2019
45
DNA hypomethylation-related overexpression of SFN, GORASP2 and ZYG11A is a novel prognostic biomarker for early stage lung adenocarcinoma. ( 30899432 )
2019
46
Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. ( 30815801 )
2019
47
Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung adenocarcinoma patients. ( 30816121 )
2019
48
Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma. ( 30816447 )
2019
49
The role of GDF15 in bone metastasis of lung adenocarcinoma cells. ( 30816507 )
2019
50
Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma. ( 30817091 )
2019
Sources

Variations for Lung Cancer Susceptibility 3

About this section

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 798)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
4 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
5 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
6 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh38 Chromosome 7, 140753393: 140753393
7 EGFR NM_005228.4(EGFR): c.2582T> A (p.Leu861Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913444 GRCh37 Chromosome 7, 55259524: 55259524
8 EGFR NM_005228.4(EGFR): c.2582T> A (p.Leu861Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913444 GRCh38 Chromosome 7, 55191831: 55191831
9 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
10 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
11 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
12 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
13 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
14 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
15 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh38 Chromosome 17, 7674250: 7674250
16 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
17 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh38 Chromosome 17, 7674254: 7674254
18 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh37 Chromosome 17, 7577572: 7577572
19 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh38 Chromosome 17, 7674885: 7674885
20 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh37 Chromosome 17, 7578203: 7578203
21 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh38 Chromosome 17, 7673764: 7673764
22 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
23 TP53 NM_000546.5(TP53): c.814G> A (p.Val272Met) single nucleotide variant Uncertain significance rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
24 TP53 NM_000546.5(TP53): c.814G> A (p.Val272Met) single nucleotide variant Uncertain significance rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
25 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
26 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
27 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
28 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
29 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh37 Chromosome 17, 7578403: 7578403
30 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh38 Chromosome 17, 7675085: 7675085
31 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
32 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
33 TP53 NM_000546.5(TP53): c.431A> C (p.Gln144Pro) single nucleotide variant Uncertain significance rs786203071 GRCh37 Chromosome 17, 7578499: 7578499
34 TP53 NM_000546.5(TP53): c.431A> C (p.Gln144Pro) single nucleotide variant Uncertain significance rs786203071 GRCh38 Chromosome 17, 7675181: 7675181
35 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
36 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
37 STK11 NM_000455.4(STK11): c.580G> A (p.Asp194Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913315 GRCh37 Chromosome 19, 1220487: 1220487
38 STK11 NM_000455.4(STK11): c.580G> A (p.Asp194Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913315 GRCh38 Chromosome 19, 1220488: 1220488
39 GNAS NM_000516.5(GNAS): c.602G> T (p.Arg201Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
40 GNAS NM_000516.5(GNAS): c.602G> T (p.Arg201Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh38 Chromosome 20, 58909366: 58909366
41 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
42 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh37 Chromosome 17, 7577114: 7577114
43 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
44 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh37 Chromosome 17, 7578265: 7578265
45 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
46 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
47 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
48 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
49 ALK NM_004304.4(ALK): c.3522C> G (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh38 Chromosome 2, 29220829: 29220829
50 ALK NM_004304.4(ALK): c.3522C> G (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh37 Chromosome 2, 29443695: 29443695

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma
Sources

Expression for Lung Cancer Susceptibility 3

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.
Sources

Pathways for Lung Cancer Susceptibility 3

About this section

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 14.41 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
2
Innate Immune System 67
Show member pathways
 14.26 AKT1 BRAF CTNNB1 EGFR ERBB2 FGFR3
3
ERK Signaling 65
Show member pathways
 14.09 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
4
Apoptotic Pathways in Synovial Fibroblasts 65
Show member pathways
 14.06 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
5
HIV Life Cycle 67
Show member pathways
 13.98 AKT1 BRAF CTNNB1 EGFR ERBB2 FGFR3
6
GPCR Pathway 65
Show member pathways
 13.97 AKT1 ALK BRAF CDK4 EGFR ERBB2
7
PEDF Induced Signaling 65
Show member pathways
 13.95 AKT1 ALK BRAF EGFR ERBB2 FGFR3
8
Activation of cAMP-Dependent PKA 65
Show member pathways
 13.82 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
9
TGF-Beta Pathway 65
Show member pathways
 13.79 AKT1 ALK BRAF EGFR ERBB2 FGFR3
10
Developmental Biology 67
Show member pathways
 13.77 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
11
Class I MHC mediated antigen processing and presentation 67
Show member pathways
 13.72 AKT1 EGFR ERBB2 FGFR3 HRAS KRAS
12
Akt Signaling 65
Show member pathways
 13.68 AKT1 ALK EGFR ERBB2 FGFR3 HRAS
13
Integrin Pathway 65
Show member pathways
 13.65 AKT1 BRAF CTNNB1 EGFR HRAS KRAS
14
Cytokine Signaling in Immune system 67
Show member pathways
 13.65 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
15
CREB Pathway 65
Show member pathways
 13.61 AKT1 ALK EGFR ERBB2 FGFR3 HRAS
16
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.56 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
17
PAK Pathway 65
Show member pathways
 13.54 AKT1 CTNNB1 EGFR ERBB2 FGFR3 HRAS
18
IL-2 Pathway 65
Show member pathways
 13.49 AKT1 BRAF EGFR ERBB2 HRAS KRAS
19
Response to elevated platelet cytosolic Ca2+ 67
Show member pathways
 13.47 AKT1 HRAS KRAS NRAS PIK3CA RAF1
20
G-Beta Gamma Signaling 65
Show member pathways
 13.37 AKT1 BRAF CTNNB1 EGFR HRAS KRAS
21
Phospholipase-C Pathway 65
Show member pathways
 13.36 AKT1 BRAF EGFR FGFR3 HRAS KRAS
22
p70S6K Signaling 65
Show member pathways
 13.35 AKT1 ALK EGFR FGFR3 HRAS KRAS
23
fMLP Pathway 65
Show member pathways
 13.3 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
24
Circadian entrainment 38
Show member pathways
 13.29 AKT1 EGFR HRAS KRAS MAP2K1 NRAS
25
TNFR1 Pathway 65
Show member pathways
 13.26 AKT1 CTNNB1 EGFR HRAS KRAS MAP2K1
26
Human cytomegalovirus infection 38
Show member pathways
 13.25 AKT1 CDK4 CTNNB1 EGFR HRAS KRAS
27
Pathways in cancer 38
13.25 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
28
PI3K-Akt signaling pathway 38
Show member pathways
 13.24 AKT1 CDK4 CTNNB1 EGFR ERBB2 FGFR3
29
Sertoli-Sertoli Cell Junction Dynamics 65
Show member pathways
 13.23 AKT1 BRAF CDK4 CTNNB1 HRAS KRAS
30
Development Angiotensin activation of ERK 23
Show member pathways
 13.23 AKT1 BRAF EGFR HRAS KRAS MAP2K1
31
Actin Nucleation by ARP-WASP Complex 65
Show member pathways
 13.21 ALK EGFR ERBB2 FGFR3 HRAS RAF1
32
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.21 AKT1 BRAF EGFR ERBB2 HRAS KRAS
33
Focal Adhesion 1 38
Show member pathways
 13.2 AKT1 BRAF CTNNB1 EGFR ERBB2 HRAS
34
CCR5 Pathway in Macrophages 65
Show member pathways
 13.17 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
35
Endometrial cancer 38
Show member pathways
 13.17 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
36
NFAT and Cardiac Hypertrophy 65
Show member pathways
 13.16 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
37
TCR Signaling (Qiagen) 65
Show member pathways
 13.15 AKT1 HRAS KRAS MAP2K1 NRAS RAF1
38
Gastric cancer 38
Show member pathways
 13.13 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
39
MAPK-Erk Pathway 68
Show member pathways
 13.12 BRAF HRAS KRAS MAP2K1 NRAS PIK3CA
40
Apoptosis Modulation and Signaling 1
Show member pathways
 13.1 AKT1 HRAS KRAS MAP2K1 NRAS PIK3CA
41
Beta-Adrenergic Signaling 65
Show member pathways
 13.1 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
42
MAPK signaling pathway 1 38
13.06 AKT1 BRAF EGFR ERBB2 FGFR3 HRAS
43
Vascular smooth muscle contraction 38
Show member pathways
 13.05 AKT1 BRAF EGFR HRAS KRAS MAP2K1
44
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 13.05 AKT1 EGFR ERBB2 FGFR3 HRAS KRAS
45
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 13.04 AKT1 BRAF HRAS KRAS MAP2K1 PIK3CA
46
Ras signaling pathway 38
Show member pathways
 13.02 AKT1 BRAF CTNNB1 EGFR FGFR3 HRAS
47
Development HGF signaling pathway 23
Show member pathways
 13.01 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
48
Glioma 38
Show member pathways
 13.01 AKT1 ALK BRAF CDK4 EGFR ERBB2
49
4-1BB Pathway 65
Show member pathways
 13 AKT1 BRAF EGFR HRAS KRAS MAP2K1
50
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.99 AKT1 CTNNB1 EGFR HRAS KRAS MAP2K1
Sources

GO Terms for Lung Cancer Susceptibility 3

About this section

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 focal adhesion GO:0005925 9.91 CTNNB1 EGFR FGFR3 KRAS MAP2K1
2 perinuclear region of cytoplasm GO:0048471 9.91 CDK4 CTNNB1 EGFR ERBB2 HRAS PRKN
3 plasma membrane GO:0005886 9.83 AKT1 ALK BRAF CTNNB1 EGFR ERBB2
4 protein-containing complex GO:0032991 9.8 AKT1 ALK CDK4 CTNNB1 EGFR PRKN
5 receptor complex GO:0043235 9.72 ALK EGFR ERBB2 FGFR3 ROS1
6 cytoplasm GO:0005737 9.55 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
7 intracellular GO:0005622 9.49 CTNNB1 TP53
8 nucleus GO:0005634 10.33 AKT1 BRAF CDK4 CTNNB1 EGFR ERBB2
9 membrane GO:0016020 10.33 AKT1 ALK BRAF CDK4 CTNNB1 EGFR
10 mitochondrion GO:0005739 10.08 AKT1 BRAF KRAS MAP2K1 PRKN RAF1
11 Golgi apparatus GO:0005794 10.03 EGFR FGFR3 HRAS MAP2K1 NFE2L2 NRAS
12 cytosol GO:0005829 10.03 AKT1 BRAF CDK4 CTNNB1 ERBB2 HRAS

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.99 HRAS MAP2K1 STK11 TP53
2 T cell receptor signaling pathway GO:0050852 9.99 BRAF HRAS PIK3CA STK11
3 regulation of cell proliferation GO:0042127 9.99 ALK BRAF CDK4 CTNNB1 EGFR SMAD4
4 phosphatidylinositol phosphorylation GO:0046854 9.97 EGFR ERBB2 FGFR3 PIK3CA
5 protein autophosphorylation GO:0046777 9.97 AKT1 ALK EGFR ERBB2 FGFR3 STK11
6 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.96 ALK EGFR ERBB2 ROS1
7 cell proliferation GO:0008283 9.96 AKT1 ALK CTNNB1 EGFR ERBB2 HRAS
8 Ras protein signal transduction GO:0007265 9.94 HRAS KRAS NRAS TP53
9 cellular response to drug GO:0035690 9.93 BRAF EGFR NFE2L2 TP53
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.93 HRAS KRAS NRAS RAF1
11 positive regulation of MAP kinase activity GO:0043406 9.92 EGFR ERBB2 HRAS KRAS
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 AKT1 BRAF EGFR PIK3CA RAF1
13 cellular response to growth factor stimulus GO:0071363 9.91 AKT1 CTNNB1 EGFR ERBB2
14 liver development GO:0001889 9.9 EGFR KRAS PIK3CA
15 positive regulation of cell growth GO:0030307 9.9 AKT1 EGFR ERBB2
16 regulation of signal transduction by p53 class mediator GO:1901796 9.9 AKT1 STK11 TP53
17 negative regulation of cell death GO:0060548 9.9 NFE2L2 PRKN SMAD4
18 positive regulation of epithelial cell proliferation GO:0050679 9.89 EGFR ERBB2 HRAS
19 negative regulation of neuron death GO:1901215 9.89 AKT1 CTNNB1 PRKN
20 epidermal growth factor receptor signaling pathway GO:0007173 9.88 AKT1 EGFR PIK3CA
21 somatic stem cell population maintenance GO:0035019 9.88 BRAF RAF1 SMAD4
22 positive regulation of MAPK cascade GO:0043410 9.88 CTNNB1 ERBB2 FGFR3 HRAS
23 negative regulation of apoptotic process GO:0043066 9.88 AKT1 BRAF CTNNB1 EGFR RAF1 TP53
24 cellular response to epidermal growth factor stimulus GO:0071364 9.87 AKT1 EGFR ERBB2
25 activation of MAPKK activity GO:0000186 9.87 BRAF EGFR RAF1
26 thymus development GO:0048538 9.87 BRAF CTNNB1 MAP2K1 RAF1
27 positive regulation of axonogenesis GO:0050772 9.86 BRAF MAP2K1 STK11
28 phosphatidylinositol 3-kinase signaling GO:0014065 9.85 AKT1 ERBB2 PIK3CA
29 ERBB2 signaling pathway GO:0038128 9.85 EGFR ERBB2 PIK3CA
30 regulation of cell motility GO:2000145 9.85 EGFR ERBB2 RAF1
31 positive regulation of protein phosphorylation GO:0001934 9.85 AKT1 EGFR ERBB2 HRAS KRAS RAF1
32 regulation of ERK1 and ERK2 cascade GO:0070372 9.84 EGFR ERBB2 ROS1
33 vasculature development GO:0001944 9.83 CTNNB1 PIK3CA STK11
34 thyroid gland development GO:0030878 9.83 BRAF MAP2K1 RAF1
35 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 BRAF EGFR FGFR3 HRAS MAP2K1
36 face development GO:0060324 9.82 BRAF MAP2K1 RAF1
37 MAPK cascade GO:0000165 9.81 BRAF EGFR ERBB2 FGFR3 HRAS KRAS
38 anoikis GO:0043276 9.78 AKT1 PIK3CA STK11
39 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.75 EGFR MAP2K1 TP53
40 phosphorylation GO:0016310 9.73 AKT1 ALK BRAF CDK4 EGFR ERBB2
41 regulation of axon regeneration GO:0048679 9.72 BRAF MAP2K1
42 response to isolation stress GO:0035900 9.71 HRAS KRAS
43 negative regulation of ERBB signaling pathway GO:1901185 9.71 EGFR ERBB2
44 trachea formation GO:0060440 9.71 CTNNB1 MAP2K1
45 response to UV-A GO:0070141 9.68 AKT1 EGFR
46 protein phosphorylation GO:0006468 9.4 AKT1 ALK BRAF CDK4 EGFR ERBB2
47 signal transduction GO:0007165 10.28 AKT1 ALK BRAF CDK4 EGFR ERBB2
48 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 AKT1 CTNNB1 EGFR HRAS NFE2L2 PRKN
49 apoptotic process GO:0006915 10.19 AKT1 FGFR3 HRAS RAF1 STK11 TP53
50 positive regulation of transcription, DNA-templated GO:0045893 10.19 AKT1 CTNNB1 EGFR MAP2K1 NFE2L2 SMAD4

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 22)
# Name